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ABSTRACT
Introduction The outbreak of the SARS- CoV-2 virus 
causing COVID-19, declared a global pandemic by the 
WHO, is a novel infection with a high rate of morbidity 
and mortality. In South Africa, 55 421 cases have been 
confirmed as of 10 June 2020, with most cases in the 
Western Cape Province. Coronavirus leaves us in a 
position of uncertainty regarding the best clinical approach 
to successfully manage the expected high number of 
severely ill patients with COVID-19. This presents a 
unique opportunity to gather data to inform best practices 
in clinical approach and public health interventions to 
control COVID-19 locally. Furthermore, this pandemic 
challenges our resolve due to the high burden of HIV and 
tuberculosis (TB) in our country as data are scarce. This 
study endeavours to determine the clinical presentation, 
severity and prognosis of patients with COVID-19 admitted 
to our hospital.
Methods and analysis The study will use multiple 
approaches taking into account the evolving nature 
of the COVID-19 pandemic. Prospective observational 
design to describe specific patterns of risk predictors 
of poor outcomes among patients with severe 
COVID-19 admitted to Tygerberg Hospital. Data will be 
collected from medical records of patients with severe 
COVID-19 admitted at Tygerberg Hospital. Using the 
Cox proportional hazards model, we will investigate the 
association between the survival time of patients with 
COVID-19 in relation to one or more of the predictor 
variables including HIV and TB.
Ethics and dissemination The research team obtained 
ethical approval from the Health Research Ethics 
Committee of the Faculty of Medicine and Health Sciences, 
Stellenbosch University and Research Committee of the 
Tygerberg Hospital. All procedures for the ethical conduct 
of scientific investigation will be adhered to by the 
research team. The findings will be disseminated in clinical 
seminars, scientific forums and conferences targeting 
clinical care providers and policy- makers.
BACKGROUND
The outbreak of coronavirus in South Africa 
is part of an evolving pandemic, which 
began when a large number of people were 
exposed to the wet animal market in Wuhan 
City, China. Current evidence points to this 
as the origin of the pandemic, which began 
in December 2019.1 The infection primarily 
Strengths and limitations of this study
 ► Our study will provide data about a unique popula-
tion with different demographic characteristics (eg, 
younger age) from those already described in the 
current literature.
 ► Our population harbours a high burden of HIV with 
7.7 million people living with HIV and tuberculosis 
(TB) incidence rate of 520 per 100 000 population; 
this gives us an opportunity to assess to the po-
tential impact of COVID-19 in TB- infected and HIV- 
infected individuals.
 ► Cape Town harbours nearly 66% of the total number 
of COVID-19 cases; the bulk of these cases come 
from previously disadvantaged areas with high lev-
els of poverty, malnutrition and where people live in 
overcrowded make shift communities. This allows 
us to investigate the socio- economic and demo-
graphic conditions of the population and its effect on 
patients with COVID-19 admitted to a hospital from 
such environments.
 ► A limitation of the research project is that as this is a 
novel infection and evolving rapidly, no sample size 
will be predetermined at this stage.
 ► This research project will collect data from 
Tygerberg Hospital and the surrounding feeder 
hospitals that account for a significant proportion 
but may not be entirely representative of the entire 
Western Cape Province, thereby limiting extrapola-
tion of conclusions.
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targets the human respiratory system and is mainly trans-
mitted by respiratory droplets and close contact. Initially, 
the virus was named 2019- nCov. Subsequently, experts 
from the International Committee on Taxonomy of 
Viruses renamed it SARS- CoV-2 virus, alluding to its simi-
larity to the severe acute respiratory syndrome (SARS) 
outbreak associated with SARS- CoVs. The disease was 
eventually named COVID-19 by the WHO on 11 February 
2020 and declared a pandemic with significant public 
health challenges.1 As of 12 June 2020, official statistics 
from the WHO reports 7 410 510 million confirmed 
cases with 418 294 deaths representing 5.6% case fatality 
rate globally.2 In South Africa, 55 421 cases have been 
reported as of 10th June 2020, with most cases being the 
Western Cape Province. Although most cases identified 
at the beginning of the epidemic were imported cases 
from overseas travellers, currently increasing numbers 
of cases are due to community transmission.3 Active case 
detection is currently performed through mass screening 
in communities, hospitals as well as at various COVID-19 
screening and testing centres. Individuals with COVID-
19- positive test are followed- up regularly and advised 
to report to hospital should they develop symptoms of 
severe disease.
Although the global case fatality is around 5.6%, South 
Africa has recorded 1210 deaths as of 10 June 2020 repre-
senting a case fatality of 2.2%. Clinically, COVID-19 pres-
ents with influenza- like symptoms of fever, rhinorrhoea, 
sneezing, sore throat, dry cough, headache, productive 
cough, dyspnoea, general malaise and gastrointestinal 
symptoms such as diarrhoea.4 5 Other clinical features 
include signs of pneumonia, acute respiratory distress 
syndrome (ARDS), acute kidney injury (AKI) and acute 
cardiac injury.5–7 The incubation period of COVID-19 
infection averages 5.2 days; the most at- risk groups of 
developing severe disease include ‘healthcare workers, 
individuals over the age of 60 years1 and patients with other 
comorbidities such as diabetes, coronary heart disease, 
chronic kidney disease (CKD), autoimmune conditions, 
cancer and hypertension. In South Africa, the popula-
tion is generally younger but potentially at higher risk 
of co- morbidities due to the non- communicable diseases 
highlighted earlier. In addition, our setting harbours 
the so- called ‘colliding epidemics’ of HIV, tuberculosis 
(TB) (both active and post- TB lung disease) and chronic 
obstructive pulmonary disease (COPD).8 Data are scarce 
on the effect of HIV, TB, post- TB lung disease and other 
prevalent chronic medical conditions in a younger popu-
lation with COVID-19.
Kidney involvement in patients with COVID-19 appears 
to be common. A study of 193 Chinese patients found 
that 59% had proteinuria, 44% had haematuria and 10% 
had elevated serum creatinine concentrations on admis-
sion.9 Cheng et al10 reported that among 710 hospital-
ised patients with COVID-19, 44% had proteinuria and 
haematuria and 26.7% had haematuria on admission. 
The prevalence of elevated serum creatinine was 15.5%. 
AKI is common and is an independent risk factor for 
mortality. There is some evidence that SARS- CoV-2 infects 
the kidney directly, inducing AKI and contributing to 
viral spread in the body.11 It is not clear whether urine can 
contain viable, infectious SARS- CoV-2. There has been 
a report from Guangzhou of the successful isolation of 
SARS- CoV-2 from the urine sample of an infected patient12; 
however, in a study of the detection of SARS- CoV-2 RNA 
in different clinical specimens, no virus was identified in 
the urine of 72 patients.13 COVID-19 infection presents a 
special threat to our patients on chronic dialysis as they 
are immunocompromised and have an increased risk 
of transmission of infection, including to hospital staff 
and family members, as well as a risk of severe and crit-
ical diseases. At a single haemodialysis centre in Wuhan, 
37 of 230 patients and 4 of 33 staff members developed 
COVID-19 infection between 14 January and 17 February 
2020.14 15
SARS- CoV-2 poses significant challenges for patients 
with pre- existing cardiovascular conditions. Such patients 
have an increased risk of severe diseases and death. The 
infection also appears to cause cardiovascular- related 
complications, including acute myocardial injury, and 
myocarditis due to direct viral myocardial damage, hypoxia, 
venous thromboembolism and arrhythmias. Because 
treatment for COVID-19 is non- specific, patients might 
be subjected to treatment that may cause drug toxicity 
and inadvertently lead patients to suffer serious cardiovas-
cular side effects. These are critical areas and very perti-
nent to the care of patients with COVID-19 that require 
thorough investigation.16 17 Furthermore, over and above 
systemic and respiratory symptoms, SARS- CoV-2 appears 
to cause severe damage to the nervous system. Previous 
reports have documented the presence of coronavirus in 
the brain or cerebral spinal fluid; a high proportion of 
patients (~36.4%) with severe COVID-19 displayed neuro-
logical symptoms, that is, headache, reduced conscious 
level and paraesthesia; there was a case of viral enceph-
alitis where genome sequencing of the cerebrospinal 
specimen revealed the presence of SARS- CoV-2 virus. It is 
therefore crucial to assess the neurological complications 
of COVID-19 in our patients.18 19
Autoimmune conditions including rheumatoid 
arthritis and systemic lupus erythematosus are typically 
associated with an increased risk of infections.20 21 The 
increased risk is related to the condition itself, as well as 
the use of immunosuppressive therapies including corti-
costeroids, cyclophosphamide and synthetic (including 
chloroquine) or biological disease- modifying antirheu-
matic drugs.22 23 Many features of the disease (fever, 
raised inflammatory markers and low lymphocytes in 
severe cases) overlap with those of autoimmune disease, 
making the diagnosis challenging.24 Data are limited 
on the incidence and outcome of COVID-19 in patients 
with autoimmune rheumatic conditions. Being immuno-
compromised with an altered cytokine profile, patients 
with severe rheumatological conditions are expected to 
be at increased risk of severe COVID-19.25 26 The effect 
of chronic immunosuppressive therapies including the 
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potential beneficial effect of chloroquine on these condi-
tions should be documented.
Rationale of the study
The number of incident cases of COVID-19 is increasing at 
a rapid rate in South Africa and, being a new infection, it 
is unclear how it will evolve in the context of a population 
with a high burden of other infectious diseases such as 
TB and HIV, and high levels of poverty, malnutrition and 
overcrowding. It is therefore important to describe the 
clinical spectrum of COVID-19 in our setting, including 
its complications and its outcomes, focussing on the 
moderate to severely ill patients who require admission 
to hospital and who may need critical care. Furthermore, 
the findings of this study have the potential hypothesis- 
generation that could be tested in further studies; in 
addition, data- generating could give on the development 
of appropriate public health interventions that could be 
effective at curbing the spread of COVID-19.
Objectives
The main objective of this study is to investigate the clin-
ical presentations of patients and healthcare workers 
admitted with COVID-19 in our setting, the evolution 
of their disease, the management and the outcomes. 
The specific objectives and expected measurements are 
detailed in table 1.
The specific objectives of the study are as follow:
1. Identify baseline factors associated with the outcome 
of the diseases (eg, HIV viral loads and immunologi-
cal markers, use of antiretrovirals for HIV treatment, 
CKD, healthcare worker, TB or previous TB, hyperten-
sion, cardiovascular disease, autoimmune rheumatic 
conditions, diabetes and other comorbidities).
2. Develop a risk score to predict the outcome of 
COVID-19 based on baseline factors appropriate for a 
low- income and middle- income setting.
3. Assess supportive and COVID-19- directed therapeutic 
interventions.
4. Assess the effect of COVID-19 on individual organ 
systems.
METHODOLOGY
Study design
The study will use multiple approaches because of the 
evolving nature of the COVID-19 pandemic. These 
approaches are as follow:
 ► Case series will provide detailed reports of the symp-
toms, signs, diagnosis, treatment and follow- up of 
patients admitted with COVID-19.
 ► A prospective observational design will be applied to 
study risk predictors of poor outcome. The primary 
outcome is in- hospital mortality.
 ► Detection of virus in urine and kidney: RNA will be 
extracted from clinical specimens and SARS- CoV-2 
Table 1 Description of outcome and exposure factors and their specific measurements
Outcome variables
Outcomes Measurements
1.Primary outcome  ► In- hospital survival/mortality
2.Secondary outcomes  ► Disease progression after admission requiring critical care
 ► In survivors, time to discharge from the ICU and hospital
 ► In those who have died and time to death
 ► Incidence of AKI, need for dialysis and recovery of kidney function
Exposure variables
Exposure factors Measurements
1.Clinical  ► Will include ‘fever, disease severity, presence of ARDS, presence of HIV 
infection and presence of other comorbidities (diabetes, obesity, heart 
failure, hypertension, existing cancer, chronic obstructive pulmonary 
disease, post- tuberculous structural lung disease)’
2.Laboratory  ► Will include ‘leucopenia, lymphopenia, thrombocytopenia, neutrophil as 
lymphocyte ratio, elevated serum creatinine, elevated C- reactive protein’, 
D- dimer, procalciltonin, CD4 and HIV viral load
3.Social demographic  ► Will include ‘age, sex, area of residence and occupation’
4.Epidemiological  ► Cases could imported, local transmission, isolated or disease clustering, 
and duration of contact with a symptomatic individual before symptoms
5.Medication  ► COVID-19- supportive therapy, COVID-19- directed therapy, antiretrovial 
treatment (ART) and, other antivirals, any other concurrent medication for 
any other indication
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; ART, antiretroviral treatment; ICU, intensive care unit; REDCap, Research 
Electronic Data Capture.
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genome detected by real- time PCR, using WHO- 
approved protocols. Positive samples will be analysed 
to determine the viral RNA concentration (viral 
load) by quantitative PCR and used to inoculate Vero 
cell cultures to detect infection- competent virus, 
using established protocols in a biosafety level three 
facility. In kidney tissue, in situ expression of viral 
nucleocapsid protein antigen will be detected by 
immunohistochemistry.11
Study setting
The study will be carried out at Tygerberg Hospital, a 
1380- bed tertiary hospital in the Eastern Metropole of 
Cape Town. The hospital provides tertiary services to 
approximately 3.5 million people from the Western Cape 
Province. Much of the population serviced by the hospital 
is from low- income areas, with a significant propor-
tion living in low- cost and informal settlements, where 
overcrowding, shared ablution and shared water facil-
ities make social distancing and the advocated hygiene 
methods difficult. Additionally, unlike current northern 
hemisphere registries, South Africa is about to enter our 
peak annual influenza season with the usual anticipated 
rise in pneumonia admissions. The impact of this on the 
COVID-19 epidemic locally is still unknown.
Sampling and sample size
As this is, a novel infection and evolving rapidly, no sample 
size will be predetermined at this stage. Power calcula-
tions will be performed for objectives that are inferential. 
The team will work with all identifiable cases to develop an 
optimal approach to clinical care and establish an epide-
miological profile of COVID-19 in the region.
Data collection and management
Data will be collected over a period of 6 months from 
June to November 2020. Data will be extracted from the 
medical records of all suspected and confirmed cases 
and entered into Research Electronic Data Capture 
(REDCap),27 a secure, web- based, electronic database 
designed to support data capture for research. The vari-
ables of interest are described further. REDCap facilitates 
easy and accurate data entry through the use of drop- down 
lists, radio buttons and checkboxes, and data validation. 
For example, date fields have a calendar control and will 
only accept valid dates. Another example is the setting 
of maximum valid values for analyte concentrations. Data 
capturers will be trained on the REDCap system using 
PDF versions of the online data capture forms and the 
data dictionary as training materials. Other measures to 
improve data quality include double data entry, and data 
cleaning through checking for inconsistencies, numer-
ical errors and missing parameters, among others. Where 
discrepancies are observed, data entered will be verified 
with the primary data source. Where possible, data will 
be validated by comparing a certain percentage of data 
in our database with that of another database. Once data 
cleaning is complete, data will be exported to Stata V.16 
(StataCorp Limited) for the analysis.
Variables measurements
The variables to collect and measure in this study are 
outlined and defined in table 1.
Baseline exposure measurements will be assessed on 
the admission of patients to guide the risk profile as well 
as the severity of COVID-19 such as age ≥60 years, high 
fever, presence of ARDS, comorbidities and diagnostic 
biomarkers such as leucopenia, high serum creatinine 
and so on. Disease progression will be monitored and 
assessment of organ function regularly done through 
conducting repeated tests including radiographic exam-
inations while the patient is admitted in the hospital.
Assessment and diagnosis
Severity grading
Cases of COVID-19 are clinically divided into mild 
(influenza- like symptoms and mild pneumonia), severe 
(presenting with dyspnoea, respiratory frequency ≥30/
min and blood oxygen saturation (SpO2) ≤93%) and crit-
ical cases (presenting with respiratory failure, septic shock, 
and with or without multiple organ failure). Patients with 
‘>50% lesions progression within 24–48 hours in pulmo-
nary radiographic imaging’ should be treated as severe 
cases28 hence admitted for clinical care in the ICU.
Diagnostic criteria
Two categories shall be defined: (a) ‘suspected cases’ and 
(b) ‘confirmed cases’.
(a)Suspected cases are those patients who meet any one 
of the epidemiological exposure history as well as any two 
of the clinical manifestations (1) fever and respiratory 
symptoms; (2) features of pneumonia; (3) a decrease of 
total white blood cell count or lymphocyte count. Second, 
suspected cases include patients who have no definite 
epidemiological exposure history but have the following 
three clinical manifestations: (1) fever and/or respira-
tory symptoms; (2) features of pneumonia; (3) decrease 
of total white blood cells count or lymphocyte count. (b) 
Confirmed cases are patients with a positive test result of 
the SARS- CoV-2 RNA by real- time fluorescence reverse 
transcription- PCR, or where the virus gene sequence is 
highly homologous to the SARS- CoV-2. Sputum, nasopha-
ryngeal/oropharyngeal swab or secretions from the lower 
respiratory tract in intubated patients where relevant will 
be collected and tested.28 29
Therapeutic interventions
Data will be collected on all therapeutic interventions, 
both supportive and directed therapy. Supportive therapy 
includes medications, such as vasopressors and antibi-
otics, and interventions, such as mechanical ventilation 
and dialysis, prescribed as part of the standard of care. 
Directed therapy will include any therapy used to lower 
the COVID-19 viral load or suppress the cytokine storm. 
We will record the specific medicine used, dose, start and 
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stop dates and any adverse events considered related to 
intervention.
Radiological examination
Chest radiography will be used to assess signs of progressive 
pulmonary infiltrates. Data will be collected from radio-
graphic and or ultrasound reports that were requested as 
part of standard clinical care for patients with COVID-19 
admitted to the hospital. The chest radiograph has shown 
to be a less sensitive diagnostic test in the early stages of 
the disease; however, one notes that the chest CT scan has 
been reported to be more sensitive at identifying pulmo-
nary abnormalities associated with coronavirus.30 Trans-
thoracic ultrasound will be documented, particularly of 
the B- lines and evidence of consolidation as per the stan-
dard technique.31
Statistical analysis
The primary outcome of the study defined as in- hospital 
mortality will be categorised as dead (yes/no). Further-
more, we will assess time to event (death) or censored 
(alive at discharge); diseases progression during hospital-
isation in the intensive care unit (from severe to critical/
or death). Frequency tabulations will be produced for 
social- demographic characteristics (age, sex, socioeco-
nomic status, smoking, alcohol and area of residence); 
and clinical characteristics (number of actual days on 
treatment prior to outcome, HIV status, Antiretroviral 
therapy (ART), definite or presumed COVID-19 diag-
nosis, treatment given prior to admission, treatment 
given while admitted, mechanical ventilation, dialysis, 
comorbidities (hypertension, diabetes, Cerebrovascular 
accident (CVA), Cardiovascular disease (CVD), COPD, 
cancer, asthma, TB and so on) and pre- existing chronic 
medication). To investigate whether significant associ-
ations exist between demographic, clinical factors and 
treatment outcome (death: yes/no), the χ2 test and multi-
variable logistic regression will be used. To determine the 
influence of clinical variables on disease progression, the 
χ2 test and multivariable logistic regression will be used. 
Log- rank test and Kaplan- Meier plots will be used to assess 
the association between time to event (discharge/death) 
and the explanatory variables. Causal diagrams will be 
used to select variables to be included in the multivariable 
logistic regression models. Factors showing a significant 
association with the outcome defined at a conservative 
10% significance level will be selected for inclusion in 
the multivariable logistic regression model.32 The logistic 
regression analysis will determine independent factors 
associated with COVID-19 treatment outcomes. Using 
the Cox proportional hazards model, we will investigate 
the association between the survival time of patients with 
COVID-19 in relation to one or more of the predictor vari-
ables outlined earlier. Here we will assume that the effect 
of any of the covariate described above does not change 
over time. We will use scaled Schoenfeld residuals to 
assess for any of the violations of the proportional hazards 
assumptions.33 To investigate longitudinal measures and 
outcomes describing the impact of COVID-19 on indi-
vidual organ systems, we will use a Generalised Estimating 
Equation method. A two- sided level of significance 
of 5% will be considered. All statistical analyses will be 
performed using Stata V.16 statistical software.
Ethics and dissemination
The research team obtained ethical approval from the 
Health Research Ethics Committee of the Faculty of 
Medicine and Health Sciences, Stellenbosch University 
and Research Committee of the Tygerberg Hospital. All 
procedures for the ethical conduct of scientific investiga-
tion will be adhered to by the research team. The find-
ings will be disseminated in clinical seminars, scientific 
forums and conferences targeting clinical care providers 
and policy- makers using virtual platforms such as webi-
nars or zoom.
Patient and public involvement
There was ‘no patient involved’ in the conceptualisa-
tion of this proposal. The results will be shared with the 
department of health where the Minister of Health will 
release the findings to the public.
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